Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +2.08%72 EV-to-EBITDA is 81.38 as of Jul. 28, 2026, which is 489% above its 10-year median of 13.82. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.01 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 359 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 94.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Orion Pharma's enterprise value is BDT35,204 Mil.
Orion Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT433 Mil. Therefore, Orion Pharma's EV-to-EBITDA for today is 81.38.
The historical rank and industry rank for Orion Pharma's EV-to-EBITDA or its related term are showing as below:
DHA:ORIONPHARM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.04 Med: 13.82 Max: 82.08
Current: 81.37
During the past 12 years, the highest EV-to-EBITDA of Orion Pharma was 82.08. The lowest was 7.04. And the median was 13.82.
DHA:ORIONPHARM's EV-to-EBITDA is ranked worse than 94.71% of 359
companies
in the Utilities - Independent Power Producers industry
Industry Median: 11.51
vs DHA:ORIONPHARM: 81.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Pharma's PE Ratio (TTM) for today is calculated as:
Orion Pharma's share price for today is BDT29.40.
Orion Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-3.108.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Orion Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: EV-to-EBITDA Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma EV-to-EBITDA vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Pharma's EV-to-EBITDA falls into.
Orion Pharma's current Enterprise Value is BDT35,204 Mil.
Orion Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT433 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EV-to-EBITDA of 81.38 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma. This is 489% above median its historical median of 13.82. Over the past decade, Orion Pharma's EV-to-EBITDA has ranged from 7.04 to 82.08. According to the industry distribution chart, Orion Pharma ranks #340 out of 359 companies in the Utilities - Independent Power Producers industry, placing it in the top 94.7%.
Is Orion Pharma's EV-to-EBITDA too high?
Orion Pharma's current EV-to-EBITDA of 81.38 is 489% above median its 10-year median of 13.82. Over the past 10 years, this metric has ranged from a low of 7.04 to a high of 82.08. The Utilities - Independent Power Producers industry median EV-to-EBITDA is 11.51. Orion Pharma's value of 81.38 is 607% above this industry median. Based on the distribution chart, Orion Pharma ranks #340 out of 359 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EV-to-EBITDA compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #340 out of 359 companies for EV-to-EBITDA. This places Orion Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 11.51. Orion Pharma's value of 81.38 is 607% above this benchmark. Historically, Orion Pharma's own EV-to-EBITDA has ranged from 7.04 to 82.08 over the past decade. While the company's 10-year median is 13.82 vs. the industry median of 11.51, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for an Utilities - Independent Power Producers company?
The median EV-to-EBITDA among Utilities - Independent Power Producers companies is 11.51, based on 359 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current EV-to-EBITDA of 81.38 is 607% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma. For the Utilities - Independent Power Producers industry, the median EV-to-EBITDA is 11.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EV-to-EBITDA is 81.38, which is 489% above median its own 10-year median of 13.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.01, compared to a current price of BDT29.40 — trading 46.9% above its estimated fair value. The current EV-to-EBITDA is 81.38, which is 489% above median its 10-year median of 13.82 and 607% above the Utilities - Independent Power Producers industry median of 11.51. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EV-to-EBITDA is 81.38 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT29.40 is trading 46.9% above its estimated GF Value™ of BDT20.01.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EV-to-EBITDA: 81.38 (489% above median its 10-year median of 13.82)
GF Value™: BDT20.01 vs. price of BDT29.40 (46.9% above fair value)
Industry Position: 607% above the Utilities - Independent Power Producers median (#340 of 359)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
